Intensive chemotherapy (IC) versus hypomethylating agents (HMA) for the treatment of younger patients with myelodysplastic syndrome (MDS) and elevated bone marrow blasts.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.7064
Abstract: 7064Background: The AZA-001 trial has shown a survival advantage for patients with high-risk MDS treated with HMA as compared to IC. However, this study was conducted mainly in an older population.... read more here.
Keywords: versus hypomethylating; chemotherapy versus; intensive chemotherapy; hypomethylating agents ... See more keywords